Non-alcoholic and alcoholic Fatty Liver Disease - two Diseases of Affluence associated with the Metabolic Syndrome and Type 2 Diabetes: the FIN-D2D Survey

Background Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aime...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC public health Jg. 10; H. 1; S. 237
Hauptverfasser: Kotronen, Anna, Yki-Järvinen, Hannele, Männistö, Satu, Saarikoski, Liisa, Korpi-Hyövälti, Eeva, Oksa, Heikki, Saltevo, Juha, Saaristo, Timo, Sundvall, Jouko, Tuomilehto, Jaakko, Peltonen, Markku
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London BioMed Central 10.05.2010
BioMed Central Ltd
Springer Nature B.V
BMC
Schlagworte:
ISSN:1471-2458, 1471-2458
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Background Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance. Methods The cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum liver enzyme concentrations, and daily alcohol consumption were assessed. Results Subjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to subjects with normal LFTs (53% and 14%, p < 0.0001 for both). Discussion and conclusion In Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with NAFLD.
AbstractList Background Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance. Methods The cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum liver enzyme concentrations, and daily alcohol consumption were assessed. Results Subjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to subjects with normal LFTs (53% and 14%, p [less than] 0.0001 for both). Discussion and conclusion In Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with NAFLD.
Abstract Background Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance. Methods The cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum liver enzyme concentrations, and daily alcohol consumption were assessed. Results Subjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to subjects with normal LFTs (53% and 14%, p < 0.0001 for both). Discussion and conclusion In Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance. The cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum liver enzyme concentrations, and daily alcohol consumption were assessed. Subjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to subjects with normal LFTs (53% and 14%, p [less than] 0.0001 for both). In Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with NAFLD.
Background Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance. Methods The cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum liver enzyme concentrations, and daily alcohol consumption were assessed. Results Subjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to subjects with normal LFTs (53% and 14%, p < 0.0001 for both). Discussion and conclusion In Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance.BACKGROUNDNon-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance.The cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum liver enzyme concentrations, and daily alcohol consumption were assessed.METHODSThe cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum liver enzyme concentrations, and daily alcohol consumption were assessed.Subjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to subjects with normal LFTs (53% and 14%, p < 0.0001 for both).RESULTSSubjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to subjects with normal LFTs (53% and 14%, p < 0.0001 for both).In Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with NAFLD.DISCUSSION AND CONCLUSIONIn Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance. The cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum liver enzyme concentrations, and daily alcohol consumption were assessed. Subjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to subjects with normal LFTs (53% and 14%, p < 0.0001 for both). In Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with NAFLD.
ArticleNumber 237
Audience Academic
Author Saaristo, Timo
Saarikoski, Liisa
Kotronen, Anna
Männistö, Satu
Yki-Järvinen, Hannele
Oksa, Heikki
Saltevo, Juha
Tuomilehto, Jaakko
Korpi-Hyövälti, Eeva
Sundvall, Jouko
Peltonen, Markku
AuthorAffiliation 4 Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
6 Tampere University Hospital, Tampere, Finland
8 Laboratory of Analytical Biochemistry, Department of Health and Functional Capacity, National Institute for Health and Welfare, Helsinki Finland
3 Minerva Medical Research Institute, Helsinki, Finland
9 Department of Public Health, University of Helsinki, Finland
1 Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland
7 Department of Internal Medicine, Central Finland Central Hospital, Jyväskylä, Finland
2 Department of Medicine, Division of Diabetes, University of Helsinki, Helsinki, Finland
5 Department of Internal Medicine, South Ostrobothnia Central Hospital, Seinäjoki, Finland
AuthorAffiliation_xml – name: 4 Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
– name: 3 Minerva Medical Research Institute, Helsinki, Finland
– name: 2 Department of Medicine, Division of Diabetes, University of Helsinki, Helsinki, Finland
– name: 5 Department of Internal Medicine, South Ostrobothnia Central Hospital, Seinäjoki, Finland
– name: 1 Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland
– name: 9 Department of Public Health, University of Helsinki, Finland
– name: 7 Department of Internal Medicine, Central Finland Central Hospital, Jyväskylä, Finland
– name: 8 Laboratory of Analytical Biochemistry, Department of Health and Functional Capacity, National Institute for Health and Welfare, Helsinki Finland
– name: 6 Tampere University Hospital, Tampere, Finland
Author_xml – sequence: 1
  givenname: Anna
  surname: Kotronen
  fullname: Kotronen, Anna
  email: anna.kotronen@helsinki.fi
  organization: Diabetes Prevention Unit, National Institute for Health and Welfare, Department of Medicine, Division of Diabetes, University of Helsinki, Minerva Medical Research Institute
– sequence: 2
  givenname: Hannele
  surname: Yki-Järvinen
  fullname: Yki-Järvinen, Hannele
  organization: Department of Medicine, Division of Diabetes, University of Helsinki
– sequence: 3
  givenname: Satu
  surname: Männistö
  fullname: Männistö, Satu
  organization: Department of Chronic Disease Prevention, National Institute for Health and Welfare
– sequence: 4
  givenname: Liisa
  surname: Saarikoski
  fullname: Saarikoski, Liisa
  organization: Diabetes Prevention Unit, National Institute for Health and Welfare
– sequence: 5
  givenname: Eeva
  surname: Korpi-Hyövälti
  fullname: Korpi-Hyövälti, Eeva
  organization: Department of Internal Medicine, South Ostrobothnia Central Hospital
– sequence: 6
  givenname: Heikki
  surname: Oksa
  fullname: Oksa, Heikki
  organization: Tampere University Hospital
– sequence: 7
  givenname: Juha
  surname: Saltevo
  fullname: Saltevo, Juha
  organization: Department of Internal Medicine, Central Finland Central Hospital
– sequence: 8
  givenname: Timo
  surname: Saaristo
  fullname: Saaristo, Timo
  organization: Tampere University Hospital
– sequence: 9
  givenname: Jouko
  surname: Sundvall
  fullname: Sundvall, Jouko
  organization: Laboratory of Analytical Biochemistry, Department of Health and Functional Capacity, National Institute for Health and Welfare
– sequence: 10
  givenname: Jaakko
  surname: Tuomilehto
  fullname: Tuomilehto, Jaakko
  organization: Department of Public Health, University of Helsinki
– sequence: 11
  givenname: Markku
  surname: Peltonen
  fullname: Peltonen, Markku
  organization: Diabetes Prevention Unit, National Institute for Health and Welfare
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20459722$$D View this record in MEDLINE/PubMed
BookMark eNp9kktvEzEUhUeoiD5gzwpZsGA1xY95mQVS1BCIFMqiZW157OvE0WTc2k6q_BV-LU7StE0FaBYzvvOdYx_rnGZHveshy94SfE5IU30iRU1yWpRNTnBOWf0iO3kYHT35Ps5OQ5hjTOqmpK-yY4qLkteUnmS_L12fy065meusQrLX6HE1kjGu0cSuwKOhDSADoBzFO7dfBeQMGhjTLaFXgGQITlkZQaM7G2cozgD9gCjbrdvVutfeLWC7yfX6BhBNPrKFCOHzlh2NL_MhHaKrpV_B-nX20sguwJv791n2a_T1-uJ7Pvn5bXwxmOQqZYi5aVqeYpVtK0kKTKXiHKAumGkJqAZrpSteSWNoYzi0pjSmrTUHxSTj2ih2lo13vtrJubjxdiH9WjhpxXbg_FRIH63qQNDatE1dEox5VUDZ8EZi1mqiKUhMa528vuy8bpbtArSCPnrZHZge_untTEzdStCmZpzVyeDjvYF3t0sIUSxsUNB1sge3DKJmrCxZU-FEvn9Gzt3S9-mmBMeUcMwKmqAPO2gq0_Ftb1zaVW0sxYDSqmGc0CJR53-h0qNhYVWqnLFpfiB49zTmQ759rxJQ7QDlXQgejFA2ymjdJrXtBMFiU2CxaajYNHQzodv8-Jlw7_0fCdlJQkL7KfjHi_in5g8yaACR
CitedBy_id crossref_primary_10_5812_ircmj_12669
crossref_primary_10_2196_30066
crossref_primary_10_14309_ajg_0000000000000833
crossref_primary_10_1097_CEH_0000000000000506
crossref_primary_10_1210_clinem_dgad418
crossref_primary_10_1007_s11739_012_0824_7
crossref_primary_10_1177_0300060513517485
crossref_primary_10_1016_j_cld_2024_06_002
crossref_primary_10_1111_apt_12673
crossref_primary_10_1530_JOE_16_0513
crossref_primary_10_1371_journal_pone_0076813
crossref_primary_10_3350_cmh_2014_20_2_154
crossref_primary_10_1016_j_hbpd_2022_10_003
crossref_primary_10_1002_cbf_2867
crossref_primary_10_1002_ijc_25797
crossref_primary_10_5812_hepatmon_25067
crossref_primary_10_1016_j_actbio_2024_06_014
crossref_primary_10_1002_hep_29247
crossref_primary_10_1186_s12944_015_0072_8
crossref_primary_10_1002_hep_28431
crossref_primary_10_1002_jcu_23398
crossref_primary_10_1007_s12072_013_9430_7
crossref_primary_10_3389_fphys_2016_00430
crossref_primary_10_14400_JDC_2014_12_3_345
crossref_primary_10_1055_a_1862_9088
crossref_primary_10_1155_2019_9727952
crossref_primary_10_1038_s41598_018_28563_y
crossref_primary_10_1016_j_atherosclerosis_2012_10_049
crossref_primary_10_1002_kjm2_12744
crossref_primary_10_3389_fendo_2018_00341
crossref_primary_10_1371_journal_pone_0060495
crossref_primary_10_3109_07853890_2014_966752
crossref_primary_10_1016_j_jhep_2019_01_035
crossref_primary_10_1038_srep38262
crossref_primary_10_1016_j_bbrc_2018_04_107
crossref_primary_10_1016_j_lpm_2019_08_008
crossref_primary_10_1002_1348_9585_12109
crossref_primary_10_1097_MOG_0000000000000627
crossref_primary_10_1097_HC9_0000000000000133
crossref_primary_10_1016_j_jhep_2017_11_006
crossref_primary_10_3390_nu11123048
crossref_primary_10_1002_gepi_21895
crossref_primary_10_1155_2014_903258
crossref_primary_10_1186_s12916_024_03315_0
crossref_primary_10_1038_s41598_020_66770_8
crossref_primary_10_1159_000375506
crossref_primary_10_1002_hep_30804
crossref_primary_10_1371_journal_pone_0171502
crossref_primary_10_14309_ajg_0000000000001141
crossref_primary_10_3390_mps5010001
crossref_primary_10_1016_j_jceh_2017_09_002
crossref_primary_10_1080_07420528_2021_1899198
Cites_doi 10.3181/00379727-176-4-RC2
10.1055/s-2005-861411
10.1210/jc.2004-2240
10.1152/ajpendo.00064.2004
10.1111/j.1572-0241.1999.01006.x
10.1016/j.bpg.2004.06.021
10.1097/00004836-200311000-00010
10.1016/0895-4356(88)90084-4
10.1002/hep.20734
10.1016/S0016-5085(99)70506-8
10.1210/jc.2007-0482
10.1016/0021-9150(86)90090-0
10.1002/hep.21496
10.1111/j.1572-0241.2003.07486.x
10.1111/j.1572-0241.2005.41500.x
10.1136/gut.2003.019984
10.1186/1471-2458-8-423
10.1093/qjmed/89.2.137
10.1161/ATVBAHA.107.147538
10.1053/jhep.2003.50193
10.3402/ijch.v66i2.18239
10.1016/S0140-6736(05)67402-8
10.7326/0003-4819-137-1-200207020-00006
10.1161/ATVBAHA.107.151092
10.1093/clinchem/18.6.499
ContentType Journal Article
Copyright Kotronen et al; licensee BioMed Central Ltd. 2010
COPYRIGHT 2010 BioMed Central Ltd.
2010 Kotronen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ©2010 Kotronen et al; licensee BioMed Central Ltd. 2010 Kotronen et al; licensee BioMed Central Ltd.
Copyright_xml – notice: Kotronen et al; licensee BioMed Central Ltd. 2010
– notice: COPYRIGHT 2010 BioMed Central Ltd.
– notice: 2010 Kotronen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: Copyright ©2010 Kotronen et al; licensee BioMed Central Ltd. 2010 Kotronen et al; licensee BioMed Central Ltd.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T2
7X7
7XB
88E
8C1
8FE
8FG
8FI
8FJ
8FK
ABJCF
ABUWG
AEUYN
AFKRA
AN0
ATCPS
AZQEC
BENPR
BGLVJ
BHPHI
C1K
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
L6V
M0S
M1P
M7S
PATMY
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PTHSS
PYCSY
7X8
5PM
DOA
DOI 10.1186/1471-2458-10-237
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health and Safety Science Abstracts (Full archive)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
ProQuest SciTech Collection
ProQuest Technology Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
One Sustainability
ProQuest Central UK/Ireland
British Nursing Database
Agricultural & Environmental Science Collection
ProQuest Central Essentials
ProQuest Central
Technology collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Engineering Collection
ProQuest Health & Medical Collection
Medical Database
Engineering Database (Proquest)
Environmental Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
Engineering Collection (ProQuest)
Environmental Science Collection
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Collection
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
ProQuest Engineering Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Agricultural & Environmental Science Collection
Health & Safety Science Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Engineering Collection
Engineering Database
ProQuest Public Health
ProQuest One Academic Eastern Edition
British Nursing Index with Full Text
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Environmental Science Collection
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Materials Science & Engineering Collection
Environmental Science Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList



MEDLINE - Academic
Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: ProQuest Publicly Available Content
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1471-2458
EndPage 237
ExternalDocumentID oai_doaj_org_article_27fb875100964e5898a03bd1d2ea027d
PMC2873937
2502976091
A226839124
20459722
10_1186_1471_2458_10_237
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Finland
GeographicLocations_xml – name: Finland
GroupedDBID ---
0R~
23N
2VQ
2WC
2XV
4.4
44B
53G
5VS
6J9
6PF
7X7
7XC
88E
8C1
8FE
8FG
8FH
8FI
8FJ
A8Z
AAFWJ
AAJSJ
AASML
AAWTL
ABDBF
ABJCF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AN0
AOIJS
ATCPS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BGLVJ
BHPHI
BMC
BNQBC
BPHCQ
BVXVI
C1A
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESTFP
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
IPNFZ
ITC
KQ8
L6V
M1P
M48
M7S
M~E
O5R
O5S
OK1
OVT
P2P
PATMY
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PTHSS
PUEGO
PYCSY
RBZ
RIG
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
U2A
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
AFFHD
CITATION
ALIPV
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T2
7XB
8FK
AZQEC
C1K
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c597t-f8b97855bba11472ac99ee743fb1ec80dcd696aff28f9ebf5ffb7d9ec3a39dfc3
IEDL.DBID RSV
ISICitedReferencesCount 52
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000278254500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1471-2458
IngestDate Fri Oct 03 12:50:57 EDT 2025
Tue Nov 04 01:59:52 EST 2025
Wed Oct 01 14:24:46 EDT 2025
Sat Oct 11 05:43:08 EDT 2025
Tue Nov 11 07:36:14 EST 2025
Sat Nov 29 10:02:38 EST 2025
Thu Apr 03 07:00:52 EDT 2025
Sat Nov 29 02:49:17 EST 2025
Tue Nov 18 21:15:07 EST 2025
Sat Sep 06 07:28:43 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Oral Glucose Tolerance Test
Abnormal Glucose Tolerance
Proton Magnetic Resonance Spectroscopy
High Alcohol Consumption
Metabolic Syndrome
Language English
License http://creativecommons.org/licenses/by/2.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c597t-f8b97855bba11472ac99ee743fb1ec80dcd696aff28f9ebf5ffb7d9ec3a39dfc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://link.springer.com/10.1186/1471-2458-10-237
PMID 20459722
PQID 902190342
PQPubID 44782
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_27fb875100964e5898a03bd1d2ea027d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_2873937
proquest_miscellaneous_733553860
proquest_journals_902190342
gale_infotracmisc_A226839124
gale_infotracacademiconefile_A226839124
pubmed_primary_20459722
crossref_citationtrail_10_1186_1471_2458_10_237
crossref_primary_10_1186_1471_2458_10_237
springer_journals_10_1186_1471_2458_10_237
PublicationCentury 2000
PublicationDate 2010-05-10
PublicationDateYYYYMMDD 2010-05-10
PublicationDate_xml – month: 05
  year: 2010
  text: 2010-05-10
  day: 10
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC public health
PublicationTitleAbbrev BMC Public Health
PublicationTitleAlternate BMC Public Health
PublicationYear 2010
Publisher BioMed Central
BioMed Central Ltd
Springer Nature B.V
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: Springer Nature B.V
– name: BMC
References Sharpe, McBride, Archbold (CR8) 1996; 89
Matteoni, Younossi, Gramlich, Boparai, Liu, McCullough (CR18) 1999; 116
Bedogni, Miglioli, Masutti, Tiribelli, Marchesini, Bellentani (CR17) 2005; 42
Saaristo, Barengo, Korpi-Hyovalti, Oksa, Puolijoki, Saltevo, Vanhala, Sundvall, Saarikoski, Peltonen, Tuomilehto (CR30) 2008; 8
Grundy (CR22) 2008; 28
Dam-Larsen, Franzmann, Andersen, Christoffersen, Jensen, Sorensen, Becker, Bendtsen (CR6) 2004; 53
Sorbi, Boynton, Lindor (CR21) 1999; 94
Alberti, Zimmet, Shaw (CR13) 2005; 366
Wannamethee, Shaper (CR25) 1991; 5
Saaristo, Peltonen, Keinanen-Kiukaanniemi, Vanhala, Saltevo, Niskanen, Oksa, Korpi-Hyovalti, Tuomilehto (CR29) 2007; 66
(CR12) 1999
Prati, Taioli, Zanella, Della Torre, Butelli, Del Vecchio, Vianello, Zanuso, Mozzi, Milani, Conte, Colombo, Sirchia (CR16) 2002; 137
Masarei, Puddey, Rouse, Lynch, Vandongen, Beilin (CR24) 1986; 60
Szczepaniak, Nurenberg, Leonard, Browning, Reingold, Grundy, Hobbs, Dobbins (CR3) 2005; 288
Kotronen, Yki-Jarvinen (CR26) 2008; 28
Bugianesi, Pagotto, Manini, Vanni, Gastaldelli, de Iasio, Gentilcore, Natale, Cassader, Rizzetto, Pasquali, Marchesini (CR19) 2005; 90
(CR15) 2005
Jepsen, Vilstrup, Mellemkjaer, Thulstrup, Olsen, Baron, Sorensen (CR7) 2003; 50
Neuschwander-Tetri, Caldwell (CR1) 2003; 37
Clark (CR4) 2006; 40
Sargin, Uygur-Bayramicli, Sargin, Orbay, Yayla (CR27) 2003; 37
(CR10) 1988; 41
Friedewald, Levy, Fredrickson (CR14) 1972; 18
Yesilova, Yaman, Oktenli, Ozcan, Uygun, Cakir, Sanisoglu, Erdil, Ates, Aslan, Musabak, Erbil, Karaeren, Dagalp (CR20) 2005; 100
Thamer, Tschritter, Haap, Shirkavand, Machann, Fritsche, Schick, Haring, Stumvoll (CR9) 2005; 37
Angulo, Hui, Marchesini, Bugianesi, George, Farrell, Enders, Saksena, Burt, Bida, Lindor, Sanderson, Lenzi, Adams, Kench, Therneau, Day (CR28) 2007; 45
Kotronen, Westerbacka, Bergholm, Pietilainen, Yki-Jarvinen (CR11) 2007; 92
Cluette, Mulligan, Noring, Doyle, Hojnacki (CR23) 1984; 176
Cortez-Pinto, Camilo (CR5) 2004; 18
Clark, Brancati, Diehl (CR2) 2003; 98
M Sargin (2148_CR27) 2003; 37
JM Clark (2148_CR2) 2003; 98
C Thamer (2148_CR9) 2005; 37
JR Masarei (2148_CR24) 1986; 60
TE Saaristo (2148_CR30) 2008; 8
Anonymous (2148_CR10) 1988; 41
H Cortez-Pinto (2148_CR5) 2004; 18
PC Sharpe (2148_CR8) 1996; 89
A Kotronen (2148_CR11) 2007; 92
JE Cluette (2148_CR23) 1984; 176
BA Neuschwander-Tetri (2148_CR1) 2003; 37
JM Clark (2148_CR4) 2006; 40
WT Friedewald (2148_CR14) 1972; 18
Anonymous (2148_CR15) 2005
D Prati (2148_CR16) 2002; 137
LS Szczepaniak (2148_CR3) 2005; 288
D Sorbi (2148_CR21) 1999; 94
S Dam-Larsen (2148_CR6) 2004; 53
T Saaristo (2148_CR29) 2007; 66
G Wannamethee (2148_CR25) 1991; 5
P Jepsen (2148_CR7) 2003; 50
A Kotronen (2148_CR26) 2008; 28
P Angulo (2148_CR28) 2007; 45
SM Grundy (2148_CR22) 2008; 28
KG Alberti (2148_CR13) 2005; 366
Z Yesilova (2148_CR20) 2005; 100
G Bedogni (2148_CR17) 2005; 42
CA Matteoni (2148_CR18) 1999; 116
E Bugianesi (2148_CR19) 2005; 90
WHO Consultation (2148_CR12) 1999
1677046 - J Hum Hypertens. 1991 Apr;5(2):59-67
18174459 - Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):629-36
16182882 - Lancet. 2005 Sep 24-30;366(9491):1059-62
12093239 - Ann Intern Med. 2002 Jul 2;137(1):1-10
12717402 - Hepatology. 2003 May;37(5):1202-19
8729555 - QJM. 1996 Feb;89(2):137-44
19113993 - BMC Public Health. 2008;8:423
17515250 - Int J Circumpolar Health. 2007 Apr;66(2):101-12
17690317 - Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):27-38
12809815 - Am J Gastroenterol. 2003 May;98(5):960-7
14696473 - Hepatogastroenterology. 2003 Nov-Dec;50(54):2101-4
10348825 - Gastroenterology. 1999 Jun;116(6):1413-9
15952086 - Horm Metab Res. 2005 Apr;37(4):246-51
14564188 - J Clin Gastroenterol. 2003 Nov-Dec;37(5):399-402
3707675 - Atherosclerosis. 1986 Apr;60(1):79-87
6463061 - Proc Soc Exp Biol Med. 1984 Sep;176(4):508-11
4337382 - Clin Chem. 1972 Jun;18(6):499-502
17393509 - Hepatology. 2007 Apr;45(4):846-54
15339742 - Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E462-8
15082596 - Gut. 2004 May;53(5):750-5
15561640 - Best Pract Res Clin Gastroenterol. 2004 Dec;18(6):1089-104
15797948 - J Clin Endocrinol Metab. 2005 Jun;90(6):3498-504
3335877 - J Clin Epidemiol. 1988;41(2):105-14
15784031 - Am J Gastroenterol. 2005 Apr;100(4):850-5
10201476 - Am J Gastroenterol. 1999 Apr;94(4):1018-22
17595248 - J Clin Endocrinol Metab. 2007 Sep;92(9):3490-7
16540768 - J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10
15895401 - Hepatology. 2005 Jul;42(1):44-52
References_xml – volume: 176
  start-page: 508
  issue: 4
  year: 1984
  end-page: 511
  ident: CR23
  article-title: Ethanol enhances de novo synthesis of high density lipoprotein cholesterol
  publication-title: Proc Soc Exp Biol Med
  doi: 10.3181/00379727-176-4-RC2
– volume: 37
  start-page: 246
  issue: 4
  year: 2005
  end-page: 251
  ident: CR9
  article-title: Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids
  publication-title: Horm Metab Res
  doi: 10.1055/s-2005-861411
– volume: 90
  start-page: 3498
  issue: 6
  year: 2005
  end-page: 3504
  ident: CR19
  article-title: Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2004-2240
– volume: 288
  start-page: E462
  issue: 2
  year: 2005
  end-page: 8
  ident: CR3
  article-title: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00064.2004
– volume: 94
  start-page: 1018
  issue: 4
  year: 1999
  end-page: 1022
  ident: CR21
  article-title: The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.1999.01006.x
– volume: 18
  start-page: 1089
  issue: 6
  year: 2004
  end-page: 1104
  ident: CR5
  article-title: Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course
  publication-title: Best Pract Res Clin Gastroenterol
  doi: 10.1016/j.bpg.2004.06.021
– volume: 37
  start-page: 399
  issue: 5
  year: 2003
  end-page: 402
  ident: CR27
  article-title: Association of nonalcoholic fatty liver disease with insulin resistance: is OGTT indicated in nonalcoholic fatty liver disease?
  publication-title: J Clin Gastroenterol
  doi: 10.1097/00004836-200311000-00010
– volume: 40
  start-page: S5
  issue: 3 Suppl 1
  year: 2006
  end-page: 10
  ident: CR4
  article-title: The epidemiology of nonalcoholic fatty liver disease in adults
  publication-title: J Clin Gastroenterol
– volume: 41
  start-page: 105
  issue: 2
  year: 1988
  end-page: 114
  ident: CR10
  article-title: The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators
  publication-title: J Clin Epidemiol
  doi: 10.1016/0895-4356(88)90084-4
– volume: 42
  start-page: 44
  issue: 1
  year: 2005
  end-page: 52
  ident: CR17
  article-title: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study
  publication-title: Hepatology
  doi: 10.1002/hep.20734
– volume: 116
  start-page: 1413
  issue: 6
  year: 1999
  end-page: 1419
  ident: CR18
  article-title: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(99)70506-8
– volume: 92
  start-page: 3490
  issue: 9
  year: 2007
  end-page: 3497
  ident: CR11
  article-title: Liver fat in the metabolic syndrome
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2007-0482
– volume: 60
  start-page: 79
  issue: 1
  year: 1986
  end-page: 87
  ident: CR24
  article-title: Effects of alcohol consumption on serum lipoprotein-lipid and apolipoprotein concentrations. Results from an intervention study in healthy subjects
  publication-title: Atherosclerosis
  doi: 10.1016/0021-9150(86)90090-0
– year: 1999
  ident: CR12
  publication-title: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus
– volume: 45
  start-page: 846
  issue: 4
  year: 2007
  end-page: 854
  ident: CR28
  article-title: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
  publication-title: Hepatology
  doi: 10.1002/hep.21496
– volume: 98
  start-page: 960
  issue: 5
  year: 2003
  end-page: 967
  ident: CR2
  article-title: The prevalence and etiology of elevated aminotransferase levels in the United States
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2003.07486.x
– volume: 100
  start-page: 850
  issue: 4
  year: 2005
  end-page: 855
  ident: CR20
  article-title: Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2005.41500.x
– volume: 53
  start-page: 750
  issue: 5
  year: 2004
  end-page: 755
  ident: CR6
  article-title: Long term prognosis of fatty liver: risk of chronic liver disease and death
  publication-title: Gut
  doi: 10.1136/gut.2003.019984
– volume: 50
  start-page: 2101
  issue: 54
  year: 2003
  end-page: 2104
  ident: CR7
  article-title: Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study
  publication-title: Hepatogastroenterology
– volume: 18
  start-page: 499
  issue: 6
  year: 1972
  end-page: 502
  ident: CR14
  article-title: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
  publication-title: Clin Chem
– volume: 8
  start-page: 423
  year: 2008
  ident: CR30
  article-title: High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-8-423
– volume: 89
  start-page: 137
  issue: 2
  year: 1996
  end-page: 144
  ident: CR8
  article-title: Biochemical markers of alcohol abuse
  publication-title: QJM
  doi: 10.1093/qjmed/89.2.137
– volume: 28
  start-page: 27
  issue: 1
  year: 2008
  end-page: 38
  ident: CR26
  article-title: Fatty liver: a novel component of the metabolic syndrome
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.107.147538
– volume: 5
  start-page: 59
  issue: 2
  year: 1991
  end-page: 67
  ident: CR25
  article-title: Alcohol intake and variations in blood pressure by day of examination
  publication-title: J Hum Hypertens
– volume: 37
  start-page: 1202
  issue: 5
  year: 2003
  end-page: 1219
  ident: CR1
  article-title: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference
  publication-title: Hepatology
  doi: 10.1053/jhep.2003.50193
– year: 2005
  ident: CR15
  article-title: StataCorp: Stata Statistical Software
  publication-title: Release 9.0
– volume: 66
  start-page: 101
  issue: 2
  year: 2007
  end-page: 112
  ident: CR29
  article-title: National type 2 diabetes prevention programme in Finland: FIN-D2D
  publication-title: Int J Circumpolar Health
  doi: 10.3402/ijch.v66i2.18239
– volume: 366
  start-page: 1059
  issue: 9491
  year: 2005
  end-page: 1062
  ident: CR13
  article-title: The metabolic syndrome--a new worldwide definition
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)67402-8
– volume: 137
  start-page: 1
  issue: 1
  year: 2002
  end-page: 10
  ident: CR16
  article-title: Updated definitions of healthy ranges for serum alanine aminotransferase levels
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-137-1-200207020-00006
– volume: 28
  start-page: 629
  issue: 4
  year: 2008
  end-page: 636
  ident: CR22
  article-title: Metabolic syndrome pandemic
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.107.151092
– volume: 37
  start-page: 1202
  issue: 5
  year: 2003
  ident: 2148_CR1
  publication-title: Hepatology
  doi: 10.1053/jhep.2003.50193
– volume: 18
  start-page: 1089
  issue: 6
  year: 2004
  ident: 2148_CR5
  publication-title: Best Pract Res Clin Gastroenterol
  doi: 10.1016/j.bpg.2004.06.021
– volume: 5
  start-page: 59
  issue: 2
  year: 1991
  ident: 2148_CR25
  publication-title: J Hum Hypertens
– volume: 176
  start-page: 508
  issue: 4
  year: 1984
  ident: 2148_CR23
  publication-title: Proc Soc Exp Biol Med
  doi: 10.3181/00379727-176-4-RC2
– volume: 66
  start-page: 101
  issue: 2
  year: 2007
  ident: 2148_CR29
  publication-title: Int J Circumpolar Health
  doi: 10.3402/ijch.v66i2.18239
– volume: 8
  start-page: 423
  year: 2008
  ident: 2148_CR30
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-8-423
– volume: 288
  start-page: E462
  issue: 2
  year: 2005
  ident: 2148_CR3
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00064.2004
– volume: 90
  start-page: 3498
  issue: 6
  year: 2005
  ident: 2148_CR19
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2004-2240
– volume: 40
  start-page: S5
  issue: 3 Suppl 1
  year: 2006
  ident: 2148_CR4
  publication-title: J Clin Gastroenterol
– volume: 53
  start-page: 750
  issue: 5
  year: 2004
  ident: 2148_CR6
  publication-title: Gut
  doi: 10.1136/gut.2003.019984
– volume: 28
  start-page: 629
  issue: 4
  year: 2008
  ident: 2148_CR22
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.107.151092
– volume: 92
  start-page: 3490
  issue: 9
  year: 2007
  ident: 2148_CR11
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2007-0482
– volume: 116
  start-page: 1413
  issue: 6
  year: 1999
  ident: 2148_CR18
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(99)70506-8
– volume: 45
  start-page: 846
  issue: 4
  year: 2007
  ident: 2148_CR28
  publication-title: Hepatology
  doi: 10.1002/hep.21496
– volume-title: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus
  year: 1999
  ident: 2148_CR12
– volume: 366
  start-page: 1059
  issue: 9491
  year: 2005
  ident: 2148_CR13
  publication-title: Lancet
  doi: 10.1016/S0140-6736(05)67402-8
– volume: 42
  start-page: 44
  issue: 1
  year: 2005
  ident: 2148_CR17
  publication-title: Hepatology
  doi: 10.1002/hep.20734
– volume: 41
  start-page: 105
  issue: 2
  year: 1988
  ident: 2148_CR10
  publication-title: J Clin Epidemiol
  doi: 10.1016/0895-4356(88)90084-4
– volume: 18
  start-page: 499
  issue: 6
  year: 1972
  ident: 2148_CR14
  publication-title: Clin Chem
  doi: 10.1093/clinchem/18.6.499
– volume: 137
  start-page: 1
  issue: 1
  year: 2002
  ident: 2148_CR16
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-137-1-200207020-00006
– volume-title: Release 9.0
  year: 2005
  ident: 2148_CR15
– volume: 100
  start-page: 850
  issue: 4
  year: 2005
  ident: 2148_CR20
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2005.41500.x
– volume: 50
  start-page: 2101
  issue: 54
  year: 2003
  ident: 2148_CR7
  publication-title: Hepatogastroenterology
– volume: 98
  start-page: 960
  issue: 5
  year: 2003
  ident: 2148_CR2
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2003.07486.x
– volume: 28
  start-page: 27
  issue: 1
  year: 2008
  ident: 2148_CR26
  publication-title: Arterioscler Thromb Vasc Biol
  doi: 10.1161/ATVBAHA.107.147538
– volume: 94
  start-page: 1018
  issue: 4
  year: 1999
  ident: 2148_CR21
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.1999.01006.x
– volume: 89
  start-page: 137
  issue: 2
  year: 1996
  ident: 2148_CR8
  publication-title: QJM
  doi: 10.1093/qjmed/89.2.137
– volume: 37
  start-page: 246
  issue: 4
  year: 2005
  ident: 2148_CR9
  publication-title: Horm Metab Res
  doi: 10.1055/s-2005-861411
– volume: 60
  start-page: 79
  issue: 1
  year: 1986
  ident: 2148_CR24
  publication-title: Atherosclerosis
  doi: 10.1016/0021-9150(86)90090-0
– volume: 37
  start-page: 399
  issue: 5
  year: 2003
  ident: 2148_CR27
  publication-title: J Clin Gastroenterol
  doi: 10.1097/00004836-200311000-00010
– reference: 18174459 - Arterioscler Thromb Vasc Biol. 2008 Apr;28(4):629-36
– reference: 12093239 - Ann Intern Med. 2002 Jul 2;137(1):1-10
– reference: 15082596 - Gut. 2004 May;53(5):750-5
– reference: 15895401 - Hepatology. 2005 Jul;42(1):44-52
– reference: 15952086 - Horm Metab Res. 2005 Apr;37(4):246-51
– reference: 10348825 - Gastroenterology. 1999 Jun;116(6):1413-9
– reference: 12717402 - Hepatology. 2003 May;37(5):1202-19
– reference: 15784031 - Am J Gastroenterol. 2005 Apr;100(4):850-5
– reference: 6463061 - Proc Soc Exp Biol Med. 1984 Sep;176(4):508-11
– reference: 16540768 - J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10
– reference: 17515250 - Int J Circumpolar Health. 2007 Apr;66(2):101-12
– reference: 3707675 - Atherosclerosis. 1986 Apr;60(1):79-87
– reference: 4337382 - Clin Chem. 1972 Jun;18(6):499-502
– reference: 3335877 - J Clin Epidemiol. 1988;41(2):105-14
– reference: 15561640 - Best Pract Res Clin Gastroenterol. 2004 Dec;18(6):1089-104
– reference: 8729555 - QJM. 1996 Feb;89(2):137-44
– reference: 14696473 - Hepatogastroenterology. 2003 Nov-Dec;50(54):2101-4
– reference: 17595248 - J Clin Endocrinol Metab. 2007 Sep;92(9):3490-7
– reference: 12809815 - Am J Gastroenterol. 2003 May;98(5):960-7
– reference: 1677046 - J Hum Hypertens. 1991 Apr;5(2):59-67
– reference: 17393509 - Hepatology. 2007 Apr;45(4):846-54
– reference: 15339742 - Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E462-8
– reference: 17690317 - Arterioscler Thromb Vasc Biol. 2008 Jan;28(1):27-38
– reference: 19113993 - BMC Public Health. 2008;8:423
– reference: 14564188 - J Clin Gastroenterol. 2003 Nov-Dec;37(5):399-402
– reference: 10201476 - Am J Gastroenterol. 1999 Apr;94(4):1018-22
– reference: 15797948 - J Clin Endocrinol Metab. 2005 Jun;90(6):3498-504
– reference: 16182882 - Lancet. 2005 Sep 24-30;366(9491):1059-62
SSID ssj0017852
Score 2.2098236
Snippet Background Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether...
Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty...
Background Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether...
Abstract Background: Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance....
Abstract Background Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance....
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 237
SubjectTerms Adult
Biostatistics
Blood & organ donations
Clinical medicine
Comorbidity
Confidence intervals
Diabetes
Diabetes Mellitus, Type 2 - epidemiology
Diagnosis
Disease
Environmental Health
Enzyme kinetics
Epidemiology
Ethanol
Fatty liver
Fatty Liver - epidemiology
Fatty Liver - metabolism
Fatty Liver, Alcoholic - epidemiology
Female
Finland
Glucose Intolerance - epidemiology
Glucose tolerance tests
Health surveys
Hospitals
Humans
India - epidemiology
Insulin resistance
Internal medicine
Liver
Liver diseases
Male
Medicine
Medicine & Public Health
Mens health
Metabolic disorders
Metabolic Syndrome - epidemiology
Methods
Middle Aged
Mortality
Population studies
Prevalence
Public Health
Research Article
Spectrum analysis
Surveys
Type 2 diabetes
Vaccine
Womens health
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5k8SCI-DbuKn0QRCFM3t3tbXQcFNZBWIW9Nf3EhSWRSWZl_4q_1qqkk52sqBeP6UeS7qpUf5Wu_oqQF4ZxlwidxNwoGxewQMQcST_TxHpuWKEK1x8UPmabDT89FZ_3Un1hTNhADzxM3CJjXgOmThFrF67kgqsk1za1mVPgUlm0voB6Rmcq7B8w3ufaScH0xllR8nGDkleLqQwtUIb5z_cWpJ63_3frvLc8XQ-dvLZ_2i9L67vkTsCTdDmM4x654er75PbwM44OZ4wekJ-bpo7VkAwXilVt6dXVWnXdJT3G-Ay6GrZraEy7H8141dLG06UPyUyoCgJ1luJPXAoIkn5yHSgT3u0kMCD0D0Enl2Y0RN20b_q264-beJWt6Mlue-EuH5Kv6_df3n2IQ1KG2IDv0cWea3A8y1JrBa4Uy5QRwjnAIV6nzvDEGluJSnmfcS-c9qX3mlnhTK5yYb3JH5GDuqndE0IFUqNWqkgdHuhVTCkAh-BRYZbAQnMdkcUoGWkCYzkmzjiXvefCK4mylChLLAFZRuTV1OP7wNbxl7ZvUdhTO-TZ7gtA-2TQPvkv7YvIS1QVidYAXs2ocKgBBoi8WnIJ6BYgKICoiBzNWsJXbGbVh6OyyWBFWikAgAnkaIwInWqxIwbG1a7ZtZLlABhzXiUReTxo5jQgTDQgWAad2UxnZyOe19Rn33qGcXCjkSgxIq9H7b56qT_N59P_MZ-H5NYYnpEmR-Sg2-7cM3LTXHRn7fZ5_43_Ah-AUBA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF5BygEJ8S6YFrQHJASSFb93lwtKSSOQSlRRkHqz9gmVkF1ip6h_hV_LjL12myJ64eh9JJ7k29mZndlvCHmpGbeRUFHItTRhBhtEyJH0M46M45plMrPdReEDtlzy42Nx6HNzGp9WOejETlGbWuMZ-VTAZiSQr-7d6c8Qi0ZhcNVX0LhJtpCoLJuQrb395eHnMYzAeJ4MsUleTGPQxGGS5R2haYKlzy_tRR1l_9-K-dLOdDVr8krotNuRFvf-U5b75K43Remsx84DcsNWD8md_hyP9teTHpHfy7oKZV9HF5plZejF00K27Tk9wNQOOu8jPTSk7a96eGpo7ejM-TooVHosWEPx_JeC8Uk_2RZwiJ925MkTui9B_5gm1CfsNG-7sYuPy3CezOnRenVmzx-Tr4v9L-8_hL6eQ6jBbWlDxxX4rHmulAQvjCVSC2EtmDBOxVbzyGhTiEI6l3AnrHK5c4oZYXUqU2GcTrfJpKor-5RQgayqhcxii3eBJZMS7EpwxrDAYKa4Csh0-GdL7cnOsebGj7JzenhRIhZKxAK2ABYC8nqccdoTfVwzdg_BMo5Diu6uoV59K_2KLxPmFDiDMTqJmc254DJKlYlNYmWUMBOQVwi1EhUJvJqW_j4ECIiUXOUMDGOwXsH-CsjuxkhQAHqje2dAWekVUFOOEAsIHXtxIubUVbZeNyVLwdZMeREF5EmP7FEgrFEgWAKT2QbmNyTe7KlOvnfk5OCBI8diQN4Mq-Pipf71ez67VoIdcntI2YijXTJpV2v7nNzSZ-1Js3rhl_wfr0FdkQ
  priority: 102
  providerName: ProQuest
Title Non-alcoholic and alcoholic Fatty Liver Disease - two Diseases of Affluence associated with the Metabolic Syndrome and Type 2 Diabetes: the FIN-D2D Survey
URI https://link.springer.com/article/10.1186/1471-2458-10-237
https://www.ncbi.nlm.nih.gov/pubmed/20459722
https://www.proquest.com/docview/902190342
https://www.proquest.com/docview/733553860
https://pubmed.ncbi.nlm.nih.gov/PMC2873937
https://doaj.org/article/27fb875100964e5898a03bd1d2ea027d
Volume 10
WOSCitedRecordID wos000278254500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMedCentral
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: RBZ
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: DOA
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: M~E
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Engineering Database (Proquest)
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: M7S
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Environmental Science Database
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: PATMY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/environmentalscience
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Health & Medical Collection
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest One Academic
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Public Health Database
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: 8C1
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Publicly Available Content
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1471-2458
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0017852
  issn: 1471-2458
  databaseCode: RSV
  dateStart: 20011201
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwED_tgRAS4jEGhI3KH5AQSNHyrG2-desqJq1VtQIanyLHsWESSlGbDu1f4a_lzkk6Mh4SfIkUPxq7Pt_Dd_4dwAvNhQlkHvhCq8JPUED4gkA_w6CwQvNEJcZdFD7lk4k4P5fTDYjauzAu2r11STpO7ba16B-EyEb9KEkdGmkU803YRmEnaDOezT6sPQdcpFHrjvxNr474cSj9v_Lin4TRzUDJG95SJ4RG9_9n-A_gXqNyskFNIw9hw5Q7cHvcONV34G59dMfqG0mP4PtkXvqqTp2Lxaos2PXbSFXVFTulaA42rJ07zGfVt3n7tmRzywa2SX3CVLP8pmB05MtQ32RjUyHp0a_NGrwE9xEyiVnEmhid5RvXdnQy8YfRkM1Wi0tztQvvR8fvjt76TQoHX6OlUvlW5GimpmmeKzS8eKS0lMag1mLz0GgRFLroy76yNhJWmtym1ua8kEbHKpaF1fFj2CrnpXkKTBKQal8loaHrv4orhaok2l-UUzDJRe7BQbuymW7wzSnNxpfM2Tmin9ESZLQEVIJL4MGrdY-vNbbHX9oeErGs2xEqtyuYLz5lzSbPIm5ztP9CsgsTkwopVBDnRVhERqH5X3jwkkgtI96BQ9OquQKBEyQUrmyAujAqrKhyebDfaYl7Xneq91pizRqes8wkqmuSEB09YOta6khhdKWZr5YZj1G9jEU_8OBJTdnrCVFaAskj7Mw7NN-ZcbemvPjs8MjR6CZYRQ9et5R_Pag__Z_P_qXxHtxpgzbCYB-2qsXKPIdb-rK6WC56sMnPuXsKfIqjsAfbh8eT6VnPHbD0KJx3hmXTk_H0Y89xix_QtVwu
linkProvider Springer Nature
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLZGhwQS4n4JG-AHEAIpauKkjY2EUKFUq9ZWlTak7ck4jg2TUDKadFP_Cv-B_8g5uW0dYm974DG-JXa-c7OPzyHkpY648UTsuVyrxA1BQLgcg376XmK5jkIVmvKi8CSazfjBgZhvkN_NXRh0q2x4Ysmok0zjHnlXgDASGK_uw_FPF5NG4eFqk0GjQsWuWZ2CxZa_Hw_h975ibPR5_9OOWycVcDXozoVreQyGU68XxwpMgYgpLYQxIEdt7BvNvUQnfdFX1jJuhYltz9o4SoTRgQpEYnUA414jmyFgnXfI5nw8nR-2xxYwMGvOQnm_C-P7Lgt7ZQBVhqnWz8m-MkXA34LgnCS86KV54ai2lICjO__Z2t0lt2tVmw4q2rhHNkx6n9yq9ilpdf3qAfk1y1JXVXmCoVilCT17GqmiWNEJuq7QYXWSRV1anGbNU04zSwe2zvNCVY11k1Dc36agXNOpKYDOcLS9OjhE-RK0_ymjtUNS_q5sOxrP3CEb0r3l4sSsHpIvV7I8j0gnzVLzhFCBUWP7KvQN3nVWkVKgN4OxiQkUw5jHDuk2SJK6DuaOOUV-yNKo432J2JOIPSwB7DnkTdvjuApkcknbjwjOth2GIC8LssU3WXM0ySIbg7HroxEcmh4XXHlBnPgJM8pjUeKQ1whtiYwSPk2r-r4HTBBDjskBKP6gnYN-6ZDttZbA4PRa9VaDalkz2Fy2kHYIbWuxI_oMpiZb5jIKQJcOeN9zyOOKktoJYQ4GETHoHK3R2NqM12vSo-9l8HXGyxiSDnnbUOPZR_1rPZ9eOoMX5MbO_nQiJ-PZ7ha52bin-N426RSLpXlGruuT4ihfPK_ZDSVfr5pK_wDlpsAA
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3rb9MwELdgoAkJ8RgDwgb4AxICKWretvlWKBUTXTWpgPbNcvyASSiZ2nRo_wp_LXeJ05HxkBAfY5_bOD6f73x3vyPkmWbcRqKMQq6VCTM4IEKOoJ9xZBzXLFOZbROFZ2w-58fH4shfuK36aPfeJdnlNCBKU9WMTo3rtjgvRjGI1DDJ8haZNEnZVXItw5JBaK0vPm28CIznSe-a_M2owVHUIvb_Kpd_OpguB01e8py2B9L09v9O5Q655VVROu545y65Yqsdsn3one075GZ3pUe7TKV75Pu8rkLVldSFZlUZevE0VU1zTmcY5UEnndOHhrT5VvdPK1o7Ona-JApVni2soXgVTEEPpYe2AZbEX1t4HIX2T9BUpgn1sTurVy3t9GAeTpIJXayXZ_Z8l3ycvv3w5l3oSzuEGiyYJnS8BPM1z8tSgUHGEqWFsBa0GVfGVvPIaFOIQjmXcCds6XLnSmaE1alKhXE6vU-2qrqyDwkVCLBaqCy2mBasmFKgYoJdhrUGs5KXARn1qyy1xz3H8htfZWv_8ELiEkhcAmyBJQjIi82I0w7z4y-0r5FxNnSI1t021MvP0m9-mTBXgl0Yo72Y2ZwLrqK0NLFJrIoSZgLyHNlOokyBV9PKp0bABBGdS45BRwZFFlSxgOwPKEEW6EH3Xs-40suilRSgxglEegwI3fTiQAyvq2y9XkmWgtqZ8iIKyIOOyzcTwnIFgiUwmA34fzDjYU918qXFKQdjHOEWA_Ky3wUXL_Wn7_noX4ifku2jyVTODubv98iNPq4jjvbJVrNc28fkuj5rTlbLJ61Y-AG9e2Ah
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Non-alcoholic+and+alcoholic+Fatty+Liver+Disease+-+two+Diseases+of+Affluence+associated+with+the+Metabolic+Syndrome+and+Type+2+Diabetes%3A+the+FIN-D2D+Survey&rft.jtitle=BMC+public+health&rft.au=Kotronen%2C+Anna&rft.au=Yki-J%C3%A4rvinen%2C+Hannele&rft.au=M%C3%A4nnist%C3%B6%2C+Satu&rft.au=Saarikoski%2C+Liisa&rft.date=2010-05-10&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2458&rft.eissn=1471-2458&rft.volume=10&rft.spage=237&rft_id=info:doi/10.1186%2F1471-2458-10-237&rft.externalDocID=A226839124
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2458&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2458&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2458&client=summon